SI9520044B - Inhibitorji Xa faktorja - Google Patents

Inhibitorji Xa faktorja Download PDF

Info

Publication number
SI9520044B
SI9520044B SI9520044A SI9520044A SI9520044B SI 9520044 B SI9520044 B SI 9520044B SI 9520044 A SI9520044 A SI 9520044A SI 9520044 A SI9520044 A SI 9520044A SI 9520044 B SI9520044 B SI 9520044B
Authority
SI
Slovenia
Prior art keywords
chg
arg
paph
leu
pro
Prior art date
Application number
SI9520044A
Other languages
English (en)
Other versions
SI9520044A (en
Inventor
Fahad Al-Obeidi
Michal Lebd
A. James Ostrem
Pavel Safar
Alena Stierandova
Peter Strop
Armin Wasler
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of SI9520044A publication Critical patent/SI9520044A/sl
Publication of SI9520044B publication Critical patent/SI9520044B/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Claims (18)

1 Patentni zahtevki 1. Spojina, ki specifično zavira aktivnost Xa faktorja, s splošno formulo X,-R1-R2-R3-X2 kjer je Xi H, acil, alkil ali arilalkil; R1 je Tyr; R2 je Ile; R3 je Arg; in je X2 izbran iz skupine, ki jo sestavljajo modificirana C-terminalna skupina, ena ali več karboksi zaščitnih skupin in ena ali več amino kislin ali druga substituenta, kjer je modificirana C-terminalna skupina modificiran^ z redukcijo C-konČne karboksi skupine v alkohol ali aldehid ali s tvorbo oralnega estra ali s substitucijo karboksi skupine s substituento, vključno njene farmacevtsko sprejemljive soli.
2. Spojina, ki specifično zavira aktivnost Xa faktorja, s splošno formulo A1-A2-A3-B kjer je Al Tyr, F(pNH2) mAph, pAph ali Nal (2), ki vsebuje 0 ali 1 amino zaščitno skupino; A2 je Ile ali Chg; A3 je Arg, PalMe (3), Dab (Ny-C3H7N), Dap (NP-C3H7N) ali Om (N3-C3H7N); in je B -H, -OH, -NH2, ena do pet amino kislin ali karboksi zaščitna skupina; 2 vključno njene farmacevtsko sprejemljive soli.
3. Spojina po zahtevku 1 ali 2, kjer je amino zaščitna skupina izbrana iz skupine, ki jo sestavljajo formil, acetil, pikoloil, terc-butilacetil, terc-butiloksikarbonil, benziloksikarbonil, 2-aril-2-0-benziloksim, aminoacil, benzoil, tožil, 3-fenoksiproprionična, 5-benzimidazolkarboksi, CClF2-CO, CF2H-CO, CF3-CF2CO, CH3-CHCI-CO, CH3-O-CO, CH3-SO2, ch3ch2-o-co, Cl2CHCO, C1CH2C0, (pOH)C6H4-CH2CH(OH)-CO, (pOH)C6H4-CH2CHOH-CO, (pOHjOsH,-OCH(CH3)CO, (pOH)C6H4-OCH2CO, 4-MeO-C6H4-CO, N-morfolinil-CO, Ph-C(NOCH2Ph)-CO, Ph-CH=CH-CO, Ph-CH2CH2CH2-CO, Ph-CH2CH2CO, trifluoroacetil, ali je substitucija N-končne amino skupine s ciklopentilkarboksi, izokinolilkarboksi ali pirazinkarboksi skupino.
4. Spojina po zahtevkih 1 do 3, kjer je farmacevtsko sprejemljiva sol kislinska adicijska sol.
5. Spojina po zahtevku 4, kjer je kislinska adicijska sol sol, tvorjena z anorgansko kislino, izbrano iz skupine, ki jo sestavljajo klorovodikova kislina, bromovodikova kislina, fosforjeva kislina, žveplova kislina ali perklorova kislina, ali je sol, tvorjena z organsko kislino, izbrano iz skupine, ki jo sestavljajo ocetna kislina, oksalna kislina, maleinska kislina, jabolčna kislina, vinska kislina, citronska kislina, jantarjeva kislina ali malonska kislina.
6. Spojina po zahtevkih 1 do 5, kjer je farmacevtsko sprejemljiva sol izbrana iz skupine, ki jo sestavljajo anorganski nitrat, sulfat, acetat, malat, format, laktat, tatrat, sukcinat, citrat in p-toluensulfonat.
7. Spojina po zahtevku 6, kjer je farmacevtsko sprejemljiva sol p-toluensulfonat. 3
8. Spojina po zahtevkih 1 in 3 do 7, kjer je Xi izbran iz skupine, ki jo sestavljajo metil, etil, n-propil, izopropil, sek-butil, 1-metilbutil, 2,2-dimetilbutil, 2-metilpentil, 2,2-dimetilpropil, n-pentil, n-heksil, ciklopentil, cikloheksil, metil-cikoheksil in ciklopropil-metilen, formil, acetil, benzoil, benzil, pikolil.
9. Spojina po zahtevkih 1 in 3 do 7, kjer je oralni ester izbran iz skupine, ki jo sestavljajo alkoksimetilne skupine, a-(Ci do C4)alkoksietilne skupine, 2-okso-l,3-dioksolen-4-ilmetilne skupine, C! do C3alkiltiometilne skupine, aciloksimetilne skupine, α-aciloksi-a-substituirane metilne skupine, l-(Ci do C4) alkiloksikarboniloksi)et-l-ilne skupine in l-(Ci do C4 alkilaminokarboniloksi)et-l-ilne skupine.
10. Spojina po zahtevku 9, kjer je oralni ester izbran iz skupine, ki jo sestavljajo metoksimetil, etoksimetil, izo-propoksimetil, metoksietil, etoksietil, propoksietil, izopropoksietil, 5-metil-2-okso-l,3-dioksolen-4-ilmetil, 5-fenil-2-okso-l,3-dioksolen-4-ilmetil, metiltiometil, etiltiometil, izopropiltiometil, pivaloiloksimetil, a-acetoksimetil, etoksikarbonil-1-metil, α-acetoksietil, 3-ftalidil, 5,6-dimetilftalidil, 1-(etoksikarboniloksi)et-1 -il in 1 -(metilaminokarboniloksi)et-1 -il.
11. Spojina po zahtevkih 1 do 10, izbrana iz skupine, ki jo sestavljajo CF3C (O) - (iBu) Phe (NH2) -Chg-Arg-Leu-Pro-NH2; Ac-pAph-Ile-Arg-Leu-Pro-NH2; CF3C(0) - (iBu)Nal (2) -Chg-Arg-Leu-Pro-NH2; Ac-Phe (31,4NH2) -Chg-Arg-Leu-Pro-NH2; 4 CF3Č,(0) -Tyr-Chg- Arg-Leu-Pro-NH2; (5 -benzimidazoii. j -Phe (NH2) -Chg - Ar g - Leu - Pr o - NH2 ; CF3C(0) - (iBu)Tyr-Ile-Arg~Leu-Pro-NH2; Ac- (Chx-CHa) Tvr-Ile-Arg-Leu-Pro-NHj; D - Tyx - Chg - Arg-Leu - Pr o - NH2 ; Ac - Trp - Chg-Arg- Leu- Pro-NH2 ; Ac -pAph - Chg - Arg - Leu - Pro - NH2 ; Ac -pAph - Chg - Arg - Gla - Pro -NHa ; Ac - (iBu)Nal (2) -Ghg-Arg-Leu-Pro-NH2; Ac-Phe (p-CONHa) -Chg-Arg-Leu-Pro-NHa; Ac -pAph- Ile-Arg-heu-Pro-NHj; Ac-Phe (pNHa) -Chg-Arg- (Me) Leu-Pro-NH2; Ac- (Chx-CHs)Tyr-Chg-Arg-Leu-Pro-NHa; Ac-pAph-Chg-Pal (3) Me-Leu-Pro-NR, ; (benzoil)- Phe (pNH,) -Chg-Arg~Leu-Pro-NH2; Ac- (2-metilpentanil) - Tyx -1 le - Arg - Leu -Pro- NH2 ; Ac- (2-metilbutil) Tyr-Ile-Arg-Leu-Pxo-NH2; Ac - Phe (pNHj) - Chg - Arg - Leu - Pro - NH2 ; Ac-Tyx-Chg-Arg-Leu-Pro-NH2 ; Ac-(iBu)-Phe(pNHj)-Chg-Arg-Leu-Pro-NH2; Ac- (Chx-CHa) -Tyr-Ile-Arg-Leu-Pro-NH2.; (2-benzofuroil)- pAph-Chg-Pal (3) Me-NH2; Ac- (iBu)Phe (pNH2) -Chg-Arg-NH2; Ac -pAph- Chg - Arg - NH2 / CF3C{0) - (iBu) Phe (pNH2) - Chg-Arg-NH2; Ac - pAph- Chg - Arg - NH2 ; Ac -pAph- Chg - Pal (3) Me -NH2 ; CF3C (O) (iBu) -Tyr-Ile-Arg-NH2; Ac-pAph-Chg-PalMe (3) -NH-CHa-Chx; Ac-pAph-Chg-PalMe(3)-NH-2CMT; Ac-pAph-Chg-PalMe(3)-NH-Chx; Ac-F(pNH2) -Chg-Dah(NV-C3NH7) -L-P-NHa; Bz-F (pNH2) -Chg-R-L-P-NH2; 5 TOS-FipNHa) -Chg-R-Ii-P-NH^; Ac-Y(3-1) -Chg-R-1,-P-NH2; y-Chg-R-L-NH^· Ac-F(pNH2)-Chg-R-ol; ciklopentil -CO-pAph-Chg-PalMe (3) -NRj,; 3-Xqc-pAph-Chg-PalMe {3)-NK,; Bzf-pAph-Chg-PalMe (3) -NH2; 3-Igc-F(pNH2) -Chg-R-L-P-NH2; Ac-F(pNH2) -Chg-R-HH-2~ tiazolil 2-furoil- 1-pAph-Chg-PalMe (3) -NH2; 5-Me-2- nienil .-CO-pAph-Chg-PalMe(3) -NH2; Ac -Nal (2} -Chg-R-NH-2-tiazolil; 2-Bzf ~F(pNH2) -Chg-R-L-P-NH2; Ac-pAph-Chg-Dab ΟΤ^Ή-,Ν) -L-P-NH2; Ac- (iBu)pAph-Chg-R-L-P-NH2; Ac-pAph-Chg-R-Gla-P-NHj,; Ac-pAph-Chg-R-Pen (CH2COOH) -P-NH*; Ac-pAph-Chg-R-L-P-NH2; Ac-F (pNH2) -Chg-R- (Me)L-P-NH2; Ac-F(pNH2)-Chg-R-OEt; · . Ac-FlpNHj) -Chg-Om (N*-C3H7N.) -L-P-NH2; Ac-F (pNH2) -Chg-R-L-P-NH2; Ac-Nal (2) -Chg-R-L-P-NHj ; Ac-pAph-Chg-Dab (NY-C3H7N) -NH2; Ac-pAph-Chg-PalMe(3) -NH2; Ac-pAph-Chg-PalMe (3) -L-P-NH2; Ac - pAph- Chg - R -NH2 ; Ac-pAph-Chg-R-OH; DIPA- (m)pAph-Chg-R-L-P-NH2? DIPA- (m) F (pNH2) -Chg-R-Ii-P-NB^; Isn-F(pNH2) -Chg-R-L-P-NH2; Pza-F (pNH2) -Chg-R-L-P-NH2; Tfa- (iBu)Y-Chg-R-L-P-NH2; 6 Tfa-(iBu) Y-I-0:m(I^-C2H7N)-L-P-NHj,* Ac-pAph-Chg-PalMe (3) -NH-CH,-Chx; Ac-pAph-Chg-PalMe (3) -NH-Chx; Bzf-pAph-Chg-PalMe (3) -NHj; Ac-pAph-Chg-PalMe (3) -L-P-NH2; Ac -pAph- Chg- PalMe (3) -NH2 ; ciklopentil -CO-pAph-Chg-PalMe(3) -NH2; 3 -lqc-pAph-Chg-PalMe (3}-NH2; 2-furoil- pAph- Chg- PalMe {3) -NH2 ; 5-Me -tienil- -CO-pAph-Chg-PalMe{3)-NK^; Ac-pAph-Chg-PalMe (3)-ol; Ac - Tyr-Ile-Arg-Leu-Ala-NH2, Ac-Tyr-Ile-Arg-Leu-Pro-NH2, Ac- (iBu) Tyr-Ile-Arg-Leu-Pro-NH2, Ac-Tyr-Ile-Arg-N(CH3) 0(CH3) , Ac-iyr- {¥{CH2NH) }-Ile-Arg-Leu-Pro-£[H2i Ac-Tyx-lle-Arg-NH-CH2 (4-piridil), Ac-Tyr-Ile- {Ψ (CH2NH) } -Arg-Leu-Pro-NH2, Ac-Tyr-Chg-Arg(NO.,) -{Ψ(CHjNH) J-Leu-NIij, Ac-Tyr-Ile-Arg-{y (COCH2)} -Gly-Pro-NH2, . . Αο-ΤγΓ-ΙΙθ-ΟΒίιίΝ^^ΗτΝ) -Leu-Ala-NH2, Ac-Tyr-Ile-PalMe (3) Tyr-Ile-Arg-NH2, D - Tyr -11 e - Ar g - Leu ~ Pr o - NH 2, Ac-(Bzl)Gly-(Chx)Gly- (3-gvanidopropil); Gly-NH2, Cyclo(Gly-Tyr-Ile~Arg-Gly) , Tfa- (iBu) Tyr-Chg-Arg-Leu-Pro-NH2, Ac -pAph- Chg - Ar g- Leu - Pro -NH2, Ac-Nal (2) -Chg-Arg-Leu-Pro-NH2, Ac-pAph - Chg-PalMe-NHj ( Ac-P-pAph-Chg-Pal (Me) -Leu-Pro-NH2, Ac-D-pAph-Chg-Pal (Me) -NH2, and Ac-Phe(pNH2) -Chg-Arg-Leu-Pro-NHj.
12. Farmacevtski sestavek, ki vsebuje spojino po zahtevkih 1 do 11. 7
13. Farmacevtski sestavek po zahtevku 12, ki nadalje obsega farmacevtsko sprejemljiv nosilec.
14. Uporaba spojine po kateremkoli od zahtevkov 1 do 11 za pripravo farmacevtskega sestavka za specifično inhibiranje aktivnosti faktorja Xa.
15. Uporaba po zahtevku 14, kjer je farmacevtski pripravek za zdravljenje kardiovaskularne motnje, izbrane iz skupine, ki jo sestavljajo restenoza po angioplastiji, sindrom respiratorne stiske odraslega, multi-organska odpoved, kap in motnja razsejanega intravaskulamega koagulacijskega strjevanja.
16. Uporaba po zahtevku 14, kjer je farmacevtski pripravek za zdravljenje komplikacij, povezanih s kirurškimi ukrepi, ki so izbrane iz skupine, ki jo sestavljata globoka venska in proksimalna venska tromboza.
17. Uporaba v zahtevku 14, kjer je farmacevtski pripravek za zmanjšanje ali zaviranje strjevanja krvi.
18. Uporaba spojine po kateremkoli od zahtevkov 1 do 11 kot antikoagulant za preprečevanje koagulacije krvnega vzorca.
SI9520044A 1994-04-26 1995-04-25 Inhibitorji Xa faktorja SI9520044B (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23305494A 1994-04-26 1994-04-26
PCT/US1995/005268 WO1995029189A1 (en) 1994-04-26 1995-04-25 FACTOR Xa INHIBITORS

Publications (2)

Publication Number Publication Date
SI9520044A SI9520044A (en) 1997-10-31
SI9520044B true SI9520044B (sl) 2004-08-31

Family

ID=22875692

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9520044A SI9520044B (sl) 1994-04-26 1995-04-25 Inhibitorji Xa faktorja

Country Status (27)

Country Link
EP (2) EP0758341B1 (sl)
JP (1) JP3655632B2 (sl)
KR (1) KR100380124B1 (sl)
CN (1) CN1181091C (sl)
AT (1) ATE262536T1 (sl)
AU (1) AU707653B2 (sl)
CA (1) CA2186497C (sl)
CZ (1) CZ296439B6 (sl)
DE (1) DE69532754T2 (sl)
DK (1) DK0758341T3 (sl)
EE (1) EE03973B1 (sl)
ES (1) ES2214500T3 (sl)
FI (1) FI120494B (sl)
HU (1) HUT76346A (sl)
IL (1) IL113505A (sl)
LT (1) LT4218B (sl)
LV (1) LV11740B (sl)
NO (1) NO318759B1 (sl)
NZ (1) NZ284977A (sl)
PL (1) PL188132B1 (sl)
PT (1) PT758341E (sl)
RU (1) RU2152954C1 (sl)
SI (1) SI9520044B (sl)
SK (1) SK286094B6 (sl)
TW (1) TW409129B (sl)
WO (1) WO1995029189A1 (sl)
ZA (1) ZA953361B (sl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA199700186A1 (ru) * 1995-02-17 1998-02-26 Басф Акциенгезельшафт Новые дипептидные амидины, используемые в качестве ингибиторов тромбина
US5747458A (en) * 1995-06-07 1998-05-05 Chiron Corporation Urokinase receptor ligands
US6069130A (en) * 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
DK0868526T3 (da) * 1995-12-20 2002-12-02 Aventis Pharma Inc Fremgangsmåde til fremstilling af N-acetyl(L)-4-cyanophenylalanin Ac-(L)-Phe(4-CN)-OH og N-acetyl-(L)-p-amidinophenylalanincyclohexylglycin-beta-(3-N-methylpyridinium)-alanin Ac-(L)-pAph-Chg-PalMe(3)-NH2
US5766932A (en) * 1995-12-20 1998-06-16 Hoechst Marion Roussel, Inc. Process for preparing N-acetyl(L)-4-cyanophenylalanine from a mixture of the corresponding D,L ethyl esters using subtilisin
US6194435B1 (en) 1996-10-11 2001-02-27 Cor Therapeutics, Inc. Lactams as selective factor Xa inhibitors
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6063794A (en) 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
US6369063B1 (en) 1997-04-14 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
WO1998046626A1 (en) 1997-04-14 1998-10-22 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
CA2285705A1 (en) * 1997-04-14 1998-10-22 Cor Therapeutics, Inc. Selective factor xa inhibitors
US7109326B2 (en) 1997-04-15 2006-09-19 Genentech, Inc. Halo-alkoxycarbonyl prodrugs
US6218382B1 (en) 1997-08-11 2001-04-17 Cor Therapeutics, Inc Selective factor Xa inhibitors
US6333321B1 (en) 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6228854B1 (en) 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
GB9727123D0 (en) * 1997-12-22 1998-02-25 Int Centre Genetic Eng & Bio Synthesis of diamines
DE69829879T2 (de) 1997-12-24 2006-03-02 Sanofi-Aventis Deutschland Gmbh Indolderivate als faktor xa inhibitoren
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
EP1016663A1 (en) * 1999-01-02 2000-07-05 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
EP1022268A1 (en) * 1999-01-02 2000-07-26 Aventis Pharma Deutschland GmbH Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
WO2000040571A1 (en) 1999-01-02 2000-07-13 Aventis Pharma Deutschland Gmbh Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity)
IL144095A0 (en) 1999-01-02 2002-05-23 Aventis Pharma Gmbh Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
EP1059302A1 (en) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
JP5088598B2 (ja) * 1999-12-14 2012-12-05 昭和電工株式会社 シアノベンジルアミン類の塩の製造方法
EP1151989A4 (en) * 1999-12-14 2009-01-21 Showa Denko Kk PROCESS FOR PRODUCING A CYANOBENZYLAMINE SALT OR ONE OF ITS DERIVATIVES
HUP0301986A2 (hu) 2000-01-28 2003-09-29 Aventis Pharma Deutschland Gmbh. Eljárás acetil-amidinofenilalanil-ciklohexilglicil-piridinioalanin-amidok elżállítására, valamint kiindulási anyagok és köztitermékek
EP1127884A1 (en) 2000-02-26 2001-08-29 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them
DE10029015A1 (de) 2000-06-15 2001-12-20 Curacyte Ag Hemmstoffe für den Gerinnungsfaktor Xa
EE200300192A (et) * 2000-12-06 2003-08-15 Aventis Pharma Deutschland Gmbh Guanidiini ja amidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline preparaatning eelravim
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
US7838560B2 (en) 2002-03-11 2010-11-23 The Medicines Company (Leipzig) Gmbh Urokinase inhibitors, production and use thereof
WO2004050637A2 (en) 2002-12-03 2004-06-17 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
EP1479680A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Azaindole derivatives as Factor Xa inhibitors
US7317027B2 (en) 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
DE10342108A1 (de) 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
EP1568698A1 (en) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
AU2005299693B2 (en) 2004-10-26 2012-07-05 Janssen Pharmaceutica, N.V. Factor Xa compounds
EP1724269A1 (en) 2005-05-20 2006-11-22 Sanofi-Aventis Deutschland GmbH Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor Xa inhibitors
DE102005044319A1 (de) 2005-09-16 2007-03-22 Curacyte Chemistry Gmbh 2-(Aminomethyl)-5-Chlor-Benzylamid-Derivate und ihre Verwendung als Hemmstoffe des Gerinnungsfaktors Xa
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
EP1918718A1 (de) * 2006-10-31 2008-05-07 Roche Diagnostics GmbH Verfahren und Vorrichtungen zur elektrochemischen Bestimmung von Faktor Xa-Inhibitoren in Blutproben
AU2008239659B2 (en) 2007-04-13 2013-09-05 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275153A (en) * 1978-08-03 1981-06-23 American Hospital Supply Corporation Analytical fluorogenic substrates for proteolytic enzymes
CA1161431A (en) * 1979-05-11 1984-01-31 Lars G. Svendsen Tripeptide derivatives
US4469679A (en) * 1983-02-16 1984-09-04 Smithkline Beckman Corporation Octapeptide vasopressin antagonists
HU191961B (en) * 1984-08-02 1987-04-28 Richter Gedeon Vegyeszet Process for producing 1,5 and 8 substituted peptides of angiotenzin-ii antagonistic activity
EP0627929B1 (en) * 1992-02-14 1998-09-30 Corvas International, Inc. Inhibitors of thrombosis

Also Published As

Publication number Publication date
NO964553D0 (no) 1996-10-25
SI9520044A (en) 1997-10-31
DK0758341T3 (da) 2004-06-28
LT96151A (en) 1997-05-26
PL317067A1 (en) 1997-03-03
NO318759B1 (no) 2005-05-02
EP0758341A1 (en) 1997-02-19
CN1181091C (zh) 2004-12-22
NZ284977A (en) 1998-09-24
CA2186497A1 (en) 1995-11-02
IL113505A0 (en) 1995-07-31
FI964317A (fi) 1996-10-25
RU2152954C1 (ru) 2000-07-20
DE69532754D1 (de) 2004-04-29
HUT76346A (en) 1997-08-28
CZ296439B6 (cs) 2006-03-15
EE03973B1 (et) 2003-02-17
CA2186497C (en) 2008-06-17
EP0758341B1 (en) 2004-03-24
LT4218B (en) 1997-09-25
LV11740A (lv) 1997-04-20
DE69532754T2 (de) 2005-03-10
CZ314096A3 (en) 1997-05-14
IL113505A (en) 1999-12-31
SK286094B6 (sk) 2008-03-05
FI964317A0 (fi) 1996-10-25
SK136696A3 (en) 1997-05-07
EP1384725A3 (en) 2007-02-21
ZA953361B (en) 1996-01-12
WO1995029189A1 (en) 1995-11-02
EE9600146A (et) 1997-04-15
ES2214500T3 (es) 2004-09-16
LV11740B (en) 1997-12-20
JP3655632B2 (ja) 2005-06-02
PL188132B1 (pl) 2004-12-31
ATE262536T1 (de) 2004-04-15
EP1384725A2 (en) 2004-01-28
CN1147261A (zh) 1997-04-09
NO964553L (no) 1996-12-27
AU707653B2 (en) 1999-07-15
PT758341E (pt) 2004-08-31
FI120494B (fi) 2009-11-13
KR100380124B1 (ko) 2003-08-02
AU2368395A (en) 1995-11-16
HU9602954D0 (en) 1996-12-30
JPH10503477A (ja) 1998-03-31
TW409129B (en) 2000-10-21

Similar Documents

Publication Publication Date Title
SI9520044B (sl) Inhibitorji Xa faktorja
Maquart et al. Matrikines in the regulation of extracellular matrix degradation
Breschi et al. Use of a specific MMP-inhibitor (galardin) for preservation of hybrid layer
Heljasvaara et al. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases
ES2567706T3 (es) Tetrapéptidos protectores para cuidado cutáneo
de Bentzmann et al. Pseudomonas aeruginosa virulence factors delay airway epithelial wound repair by altering the actin cytoskeleton and inducing overactivation of epithelial matrix metalloproteinase–2
McCarthy et al. Reconstitution of autophagy ameliorates vascular function and arterial stiffening in spontaneously hypertensive rats
JPS60500870A (ja) 酵素阻害剤
SI0670310T1 (sl) Bisulfitni adukti arginin aldehidov, ki so uporabni kot inhibitorji trombina in kot antikoagulanti
UA89684C2 (ru) Двухслойная фармацевтическая дозированная форма с модифицированным высвобождением нимесулида
Lungarella et al. Pulmonary vascular injury in pancreatitis: evidence for a major role played by pancreatic elastase
CN104053673A (zh) 凝血酶结合抗体分子及其用途
Bakowska et al. Collagenase and gelatinase activities in bronchoalveolar lavage fluids during bleomycin‐induced lung injury
EP1257582B1 (en) Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity
Prasa et al. The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation
Stefanovič et al. Cell surface aminopeptidase A and N activities in human glomerular epithelial cells
BR9908479A (pt) Composições farmacêuticas que contêm o inibidor de fosfolipase [[3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil_-1h-indol- 4-il]óxil] acetato de sódio
Taki et al. Gastrointestinal absorption of peptide drug: quantitative evaluation of the degradation and the permeation of metkephamid in rat small intestine.
Ingerman-Wojenski et al. Model system to study interaction of platelets with damaged arterial wall: II. Inhibition of smooth muscle cell proliferation by dipyridamole and AH-P719
US20150031633A1 (en) Bifunctional peptide
Gacko et al. Activities of proteases in parietal thrombus of aortic aneurysm
AU2003294360B2 (en) Method to increase fibronectin
Irazusta et al. Effects of hydrosaline treatments on prolyl endopeptidase activity in rat tissues
Frankel et al. Induction of unilateral pulmonary fibrosis in the rat by cadmium chloride
Zhou et al. Study on related indexes of the coagulation and fibrinolytic system after renal ischemia reperfusion injury in Wistar rats

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20111128